{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T06:26:38Z","timestamp":1794723998028,"version":"4.9.1"},"reference-count":27,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"unspecified","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,11,12]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>On 1 January 2023, Ontario expanded pharmacists\u2019 scope of practice, allowing them to prescribe medications for 13 minor ailments, including antibiotics for uncomplicated urinary tract infections (UTIs) and Lyme disease (LD) prophylaxis. This study evaluates pharmacist billing claims and pharmacist and physician antibiotic-prescribing rates before and after policy implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>An interrupted time series analysis measuring changes in prescribing trends post-implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>This retrospective study analysed visit claims and antibiotic prescribing for UTIs and LD prophylaxis before policy implementation (2022) and after (2023\u20132024) in Ontario.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Data from Ontarians<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary outcome measures<\/jats:title>\n                    <jats:p>Prescribing rates were standardised per 1000 inhabitants, stratified by provider type, patient age and sex, and antibiotic type.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2023 and 2024, pharmacists submitted over 1.47\u2009million minor ailment claims, with UTIs making up 34.2% and LD prophylaxis making up 2.6% of total claims. UTI claims were primarily for women aged 25\u201364, and LD prophylaxis peaked in spring and fall. Pharmacist prescribing of eligible urinary drugs in females increased by 33.3 per 1000 person-years (95%\u2009CI 30.8 to 36.6) while physician prescribing decreased by 23.3 (95% CI \u221232.2 to \u221215.3), leading to a modest net increase of 10.1 (95% CI 0.0 to 18.7). Pharmacist prescribing of doxycycline was offset by decreased physician prescribing, resulting in no change (0.0, 95%\u2009CI \u22121.0 to 0.9). Pharmacist prescribing for other antibiotics was low over the study timeframe, while physician prescribing increased, which was driven by increased prescribing of penicillins and macrolides.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There was a clear increase in pharmacist prescribing for eligible drugs in the eligible population post-policy implementation. Pharmacists in Ontario appear to be prescribing within policy limits for uncomplicated UTIs and LD prophylaxis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-107109","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T03:45:34Z","timestamp":1764301534000},"page":"e107109","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of community pharmacist antibiotic prescribing for minor ailments: an interrupted time series analysis"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6780-5378","authenticated-orcid":false,"given":"Valerie","family":"Leung","sequence":"first","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario, Canada"},{"name":"Toronto East Health Network Michael Garron Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5467-6776","authenticated-orcid":false,"given":"Bradley","family":"Langford","sequence":"additional","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario, Canada"},{"name":"University of Toronto Dalla Lana School of Public Health, Toronto, Ontario, Canada"},{"name":"Hotel Dieu Shaver Health and Rehabilitation Centre, St. Catharines, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin A","family":"Brown","sequence":"additional","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario, Canada"},{"name":"University of Toronto Dalla Lana School of Public Health, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorsa","family":"Ghahramani","sequence":"additional","affiliation":[{"name":"University of Toronto Leslie Dan Faculty of Pharmacy, Toronto, Ontario, Canada"},{"name":"ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Hoang","sequence":"additional","affiliation":[{"name":"University of Toronto Leslie Dan Faculty of Pharmacy, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Oberai","sequence":"additional","affiliation":[{"name":"Wawa Family Health Team, Wawa, Ontario, Canada"},{"name":"Northern Ontario School of Medicine University, Wawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1911-6129","authenticated-orcid":false,"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[{"name":"University of Toronto Leslie Dan Faculty of Pharmacy, Toronto, Ontario, Canada"},{"name":"ICES, Toronto, Ontario, Canada"},{"name":"Women\u2019s College Hospital Institute for Health System Solutions and Virtual Care, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8827-3764","authenticated-orcid":false,"given":"Nick","family":"Daneman","sequence":"additional","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario, Canada"},{"name":"University of Toronto Institute of Health Policy Management and Evaluation, Toronto, Ontario, Canada"},{"name":"Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Saqib","sequence":"additional","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Public Health Ontario, Toronto, Ontario, Canada"},{"name":"University of Toronto Dalla Lana School of Public Health, Toronto, Ontario, Canada"},{"name":"Unity Health Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"2026111421194351000_15.11.e107109.1","unstructured":"Canadian Pharmacists\u2019 Association . Pharmacists\u2019 scope of practice in Canada. 2025. Available: https:\/\/www.pharmacists.ca\/cpha-ca\/assets\/File\/cpha-on-the-issues\/Scope_Practice_EN.pdf"},{"key":"2026111421194351000_15.11.e107109.2","doi-asserted-by":"publisher","DOI":"10.46747\/cfp.700708441"},{"key":"2026111421194351000_15.11.e107109.3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/IJGM.S99540","article-title":"Pharmacist-led minor ailment programs: a Canadian perspective","volume":"9","author":"Taylor","year":"2016","journal-title":"Int J Gen Med"},{"key":"2026111421194351000_15.11.e107109.4","article-title":"Pharmacist Prescribing for Minor Ailments Service Development: The Experience in Ontario","volume":"9","author":"Nakhla","year":"2021","journal-title":"Pharmacy (Basel)"},{"key":"2026111421194351000_15.11.e107109.5","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/1715163517723352","article-title":"Incorporating assessment and prescribing for ambulatory ailments skills into practice: An environmental scan of continuing education for pharmacist prescribing in Canada","volume":"150","author":"Habicht","year":"2017","journal-title":"Can Pharm J"},{"key":"2026111421194351000_15.11.e107109.6","unstructured":"Executive officer notice: update to funding for minor ailment services in Ontario pharmacies. 2024. Available: https:\/\/www.ontario.ca\/files\/2024-01\/moh-executive-officer-notice-en-2024-01-04.pdf"},{"key":"2026111421194351000_15.11.e107109.7","unstructured":"Minor ailments: drug classes and specified drugs. (Schedule 4 of O. reg. 256\/24). 2024. Available: https:\/\/www.ocpinfo.com\/wp-content\/uploads\/2023\/07\/minor-ailments-drug-classes-and-specified-drugs.pdf"},{"key":"2026111421194351000_15.11.e107109.8","unstructured":"How can you help your patients with an uncomplicated UTI? 2021. Available: https:\/\/www.pharmacists.ca\/cpha-ca\/assets\/File\/education-practice-resources\/Uncomplicated_UTI.pdf"},{"key":"2026111421194351000_15.11.e107109.9","unstructured":"Assessment and prescribing algorithm for pharmacists: antibiotic prophylaxis to prevent lyme disease following a tick bite. 2024. Available: https:\/\/www.publichealthontario.ca\/-\/media\/Documents\/L\/2023\/lyme-disease-assessment-prescribing-algorithm-antibiotic-prophylaxis.pdf"},{"key":"2026111421194351000_15.11.e107109.10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1715163521999417","article-title":"Community pharmacist prescribing of antimicrobials: A systematic review from an antimicrobial stewardship perspective","volume":"154","author":"Wu","year":"2021","journal-title":"Can Pharm J"},{"key":"2026111421194351000_15.11.e107109.11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/1715163518781175","article-title":"Outcomes of Urinary Tract Infection Management by Pharmacists (R x OUTMAP): A study of pharmacist prescribing and care in patients with uncomplicated urinary tract infections in the community","volume":"151","author":"Beahm","year":"2018","journal-title":"Can Pharm J"},{"key":"2026111421194351000_15.11.e107109.12","first-page":"205","article-title":"Antimicrobial utilization and stewardship in patients with uncomplicated urinary tract infections managed by pharmacists in the community: A sub-study of the RxOUTMAP trial","volume":"6","author":"Beahm","year":"2021","journal-title":"J Assoc Med Microbiol Infect Dis Can"},{"key":"2026111421194351000_15.11.e107109.13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/17151635241290519","article-title":"Lyme disease chemoprophylaxis prescribing before and after pharmacist prescriptive authority in Nova Scotia","volume":"158","author":"Bell","year":"2025","journal-title":"Can Pharm J"},{"key":"2026111421194351000_15.11.e107109.14","unstructured":"Pharmacists prescribing for common ailments frequently asked questions. 2023. Available: https:\/\/www.oma.org\/siteassets\/oma\/media\/public\/faqs-on-pharmacists-prescribing-for-common-ailments.pdf"},{"key":"2026111421194351000_15.11.e107109.15","unstructured":"Persaud S . We\u2019re already over-prescribing antibiotics. Allowing pharmacists to prescribe medications could make a serious problem worse. Toronto Star; 2023. Available: https:\/\/www.thestar.com\/opinion\/contributors\/we-re-already-over-prescribing-antibiotics-allowing-pharmacists-to-prescribe-medications-could-make-a-serious\/article_914ecb4e-e3fb-5fd8-a7ef-cbdd1279d627.html"},{"key":"2026111421194351000_15.11.e107109.16","unstructured":"Population projections. 2012. Available: https:\/\/data.ontario.ca\/dataset\/population-projections"},{"key":"2026111421194351000_15.11.e107109.17","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1715163517723036","article-title":"The assessment and management of urinary tract infections in adults: Guidelines for pharmacists","volume":"150","author":"Beahm","year":"2017","journal-title":"Can Pharm J"},{"key":"2026111421194351000_15.11.e107109.18","unstructured":"Guidelines for ATC classification and DDD assignment 2013. 2012. Available: https:\/\/atcddd.fhi.no\/filearchive\/publications\/1_2013guidelines.pdf"},{"key":"2026111421194351000_15.11.e107109.19","doi-asserted-by":"crossref","unstructured":"Wood SN . Generalized additive models: an introduction with R. 2nd edn. Chapman and Hall\/CRC, 2017.","DOI":"10.1201\/9781315370279"},{"key":"2026111421194351000_15.11.e107109.20","unstructured":"Ontario College of Pharmacists . 5 key questions and answers about adapting prescriptions. Pharm Connect; 2023. Available: https:\/\/pharmacyconnection.ca\/5-key-questions-and-answers-about-adapting-prescriptions\/"},{"key":"2026111421194351000_15.11.e107109.21","unstructured":"Ontario College of Pharmacists . Renewing prescriptions: five important reminders for pharmacists. Pharm Connect; 2025. Available: https:\/\/pharmacyconnection.ca\/renewing-prescriptions-five-important-reminders-for-pharmacists\/"},{"key":"2026111421194351000_15.11.e107109.22","unstructured":"Summary safety review - fluoroquinolones - assessing the potential risk of persistent and disabling side effects. 2017. Available: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medeffect-canada\/safety-reviews\/summary-safety-review-fluoroquinolones-assessing-potential-risk-persistent-disabling-effects.html"},{"key":"2026111421194351000_15.11.e107109.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010077","article-title":"Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study","volume":"5","author":"Daneman","year":"2015","journal-title":"BMJ Open"},{"key":"2026111421194351000_15.11.e107109.24","unstructured":"Reports for PMS-nitrofurantoin BID. n.d. Available: https:\/\/www.drugshortagescanada.ca\/drug\/56750"},{"key":"2026111421194351000_15.11.e107109.25","unstructured":"Nelder M . Update on Lyme Disease Prevention and Control: Technical Report; Toronto, ON, CA Public Health Ontario; 2016. Available: https:\/\/www.publichealthontario.ca\/-\/media\/Documents\/Lab\/lyme-disease-prevention-technical.pdf?rev=edabb26ea99f41dfa6c247b8878d2aab&sc_lang=en"},{"key":"2026111421194351000_15.11.e107109.26","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab533","article-title":"The Impact of COVID-19 on Outpatient Antibiotic Prescriptions in Ontario, Canada; An Interrupted Time Series Analysis","volume":"8","author":"Kitano","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026111421194351000_15.11.e107109.27","unstructured":"Ontario antimicrobial stewardship program & antimicrobial resistance comparison tool. 2022. Available: https:\/\/www.publichealthontario.ca\/en\/Health-Topics\/Antimicrobial-Stewardship\/ASP-ComparisonTool"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-107109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T05:24:02Z","timestamp":1794720242000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-107109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,27]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjopen-2025-107109"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-107109","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}